Sugi Predict

Sugi Predict / Compounds / SCHEMBL2880443

SCHEMBL2880443

SCHEMBL2880443

Cc1cccc(OCc2ccccc2)c1C

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.81
▸ L3MBTL1 Q9Y468 3/20 0.81
▸ TDP1 Q9NUW8 2/20 0.81
▸ MAPK1 P28482 1/20 0.81
▸ RAB9A P51151 2/20 0.60
▸ LMNA P02545 1/20 0.60
▸ HTR1A P08908 3/20 0.56
▸ ADRA1A P35348 3/20 0.56
▸ ADRA1D P25100 2/20 0.56
▸ ADRA1B P35368 2/20 0.56
▸ RXRA P19793 1/20 0.54
▸ RXRB P28702 1/20 0.54
▸ RXRG P48443 1/20 0.54
▸ HTR6 P50406 2/20 0.54
▸ LIPE Q05469 1/20 0.53
▸ NPC1 O15118 1/20 0.52
▸ CASP3 P42574 1/20 0.52
▸ SENP8 Q96LD8 1/20 0.52
▸ SENP7 Q9BQF6 1/20 0.52
▸ SENP6 Q9GZR1 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19612191 0.90 MAPT (1.00) MAPTL3MBTL1TDP1MAPK1HTR1A
SCHEMBL265584 0.86 MAPK1 (0.70) MAPTL3MBTL1TDP1MAPK1RAB9A
SCHEMBL29874217 0.86 MAPK1 (0.70) MAPTL3MBTL1TDP1MAPK1RAB9A
SCHEMBL9007487 0.84 MAPT (0.80) MAPTL3MBTL1TDP1MAPK1HTR1A
Ammonia Solution, Strong SCHEMBL27910258 0.83 MAPT (0.67) MAPTL3MBTL1TDP1MAPK1RAB9A
SCHEMBL20140075 0.83 MAPT (0.67) MAPTL3MBTL1TDP1MAPK1HTR1A
SCHEMBL1253794 0.83 MAPT (0.85) MAPTL3MBTL1TDP1MAPK1HTR1A
SCHEMBL19612388 0.83 L3MBTL1 (0.67) MAPTL3MBTL1TDP1MAPK1HTR1A
SCHEMBL23043786 0.81 MAPT (0.65) MAPTL3MBTL1TDP1MAPK1HTR1A
SCHEMBL19086324 0.81 TDP1 (0.76) MAPTL3MBTL1TDP1MAPK1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112209900-A Method for preparing 4-cyclohexylmorpholine compound by using lignin model compound 华东师范大学 2021-01-12 — — CN claimed
US-7641880-B2 Room temperature synthesis of GaN nanopowder OHIO UNIVERSITY (US) 2010-01-05 — — US claimed
US-20070297969-A1 Room temperature synthesis of GaN nanopowder OHIO UNIVERSITY (US) 2007-12-27 — — US claimed
CN-112209900-A Method for preparing 4-cyclohexylmorpholine compound by using lignin model compound 华东师范大学 2021-01-12 — — CN disclosed
US-10370388-B2 Heterocyclic compounds and methods of their use NOVARTIS AG (CH) 2019-08-06 — — US disclosed
US-20170145032-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF THEIR USE SPINIFEX PHARMACEUTICALS PTY LTD (AU) 2017-05-25 — — US disclosed
US-20170145032-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF THEIR USE SPINIFEX PHARMACEUTICALS PTY LTD (AU) 2017-05-25 — — US disclosed
US-9624243-B2 Heterocyclic compounds and methods of their use NOVARTIS AG (CH) 2017-04-18 — — US disclosed
US-9624243-B2 Heterocyclic compounds and methods of their use NOVARTIS AG (CH) 2017-04-18 — — US disclosed
US-20140378430-A1 Heterocyclic Compounds and Methods of Their Use SPINIFEX PHARMACEUTICALS PTY LTD (AU) 2014-12-25 — — US disclosed
US-20140378430-A1 Heterocyclic Compounds and Methods of Their Use SPINIFEX PHARMACEUTICALS PTY LTD (AU) 2014-12-25 — — US disclosed
US-20080188423-A1 PI-3 KINASE INHIBITOR PRODRUGS SIGNALRX PHARMACEUTICALS, INC. 2008-08-07 — — US disclosed
US-7396828-B2 PI-3 kinase inhibitor prodrugs SEMAFORE PHARMACEUTICALS, INC. (US) 2008-07-08 — — US disclosed
US-7396828-B2 PI-3 kinase inhibitor prodrugs SEMAFORE PHARMACEUTICALS, INC. (US) 2008-07-08 — — US disclosed
WO-2008054522-A2 ROOM TEMPERATURE SYNTHESIS OF GAN NANOPOWDER OHIO UNIVERSITY (US) 2008-05-08 — — WO disclosed
US-20070297969-A1 Room temperature synthesis of GaN nanopowder OHIO UNIVERSITY (US) 2007-12-27 — — US disclosed
EP-0486745-A1 Improved solvents for chromogens useful in the manufacture of carbonless copying paper MONSANTO EUROPE S.A./N.V. (BE) 1992-05-27 — — EP disclosed
US-4704401-A HYPOTENSIVE AGENTS RORER PHARMACEUTICAL CORPORATION (US) 1987-11-03 — — US disclosed
US-4564640-A Amidinoureas substituted in both the urea and amidino nitrogen positions WILLIAM H. RORER, INC. (US) 1986-01-14 — — US disclosed
US-4487779-A HYPOTENSIVE AGENTS WILLIAM H. RORER, INC. (US) 1984-12-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10370388-B2 Heterocyclic compounds and methods of their use AGTR2, AGTR1, BDKRB2 MAPT 3922/4885L3MBTL1 4805/4885TDP1 3356/4885
US-20140378430-A1 Heterocyclic Compounds and Methods of Their Use AGTR2, AGTR1, BDKRB2 MAPT 3894/4885L3MBTL1 4807/4885TDP1 3355/4885
US-20170145032-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF THEIR USE AGTR2, AGTR1, BDKRB2 MAPT 3894/4885L3MBTL1 4807/4885TDP1 3355/4885
US-20080188423-A1 PI-3 KINASE INHIBITOR PRODRUGS PI4KA, PI4KB, PI4K2B MAPT 3144/4885L3MBTL1 1504/4885TDP1 733/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.